These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 35898513)

  • 1. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
    Lin L; Wu Y; Hang H; Lu J; Ding Y
    Front Immunol; 2022; 13():853891. PubMed ID: 35898513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
    J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD.
    Wang L; Xia R; Li X; Shan J; Wang S
    Front Immunol; 2023; 14():1293100. PubMed ID: 38259484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Wang M; Xia D; Sun L; Bi J; Xie K; Wang P
    Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
    Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
    Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
    Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of CSF neopterin levels in CNS demyelinating diseases.
    Miyaue N; Hosokawa Y; Yamanishi Y; Tada S; Ando R; Nagai M
    J Neurol Sci; 2022 Oct; 441():120385. PubMed ID: 36027640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMOSD and MOGAD: an evolving disease spectrum.
    Uzawa A; Oertel FC; Mori M; Paul F; Kuwabara S
    Nat Rev Neurol; 2024 Oct; 20(10):602-619. PubMed ID: 39271964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.